Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LVTX 
LAVA Therapeutics NV (LVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LVTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.4
1 Year Target Price $1.4
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.06% | Avg. Invested days 50 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.72M USD | Price to earnings Ratio - | 1Y Target Price 1.4 |
Price to earnings Ratio - | 1Y Target Price 1.4 | ||
Volume (30-day avg) 4 | Beta 0.49 | 52 Weeks Range 0.85 - 2.09 | Updated Date 09/17/2025 |
52 Weeks Range 0.85 - 2.09 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -521.84% |
Management Effectiveness
Return on Assets (TTM) -21.3% | Return on Equity (TTM) -90.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16448005 | Price to Sales(TTM) 7.96 |
Enterprise Value -16448005 | Price to Sales(TTM) 7.96 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA 0.81 | Shares Outstanding 26305300 | Shares Floating 10221975 |
Shares Outstanding 26305300 | Shares Floating 10221975 | ||
Percent Insiders 33.55 | Percent Institutions 36.39 |
Upturn AI SWOT
LAVA Therapeutics NV
Company Overview
History and Background
LAVA Therapeutics NV, founded in 2016, is a biotechnology company focused on developing bispecific gamma-delta T cell engagers to treat cancer. It leverages its Gammabody platform to activate gamma-delta T cells for tumor cell killing.
Core Business Areas
- Immuno-Oncology: Development of bispecific antibodies that activate gamma-delta T cells to fight cancer.
Leadership and Structure
The company is led by a management team with experience in biopharmaceutical development and is governed by a board of directors.
Top Products and Market Share
Key Offerings
- LAVA-051: A bispecific gamma-delta T cell engager targeting EGFR for the treatment of solid tumors. Currently in Phase 1/2a clinical trials. Competitors include companies developing similar T-cell engagers and EGFR-targeted therapies.
- LAVA-1207: A bispecific gamma-delta T cell engager targeting PSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 1/2a clinical trials. Competitors include companies developing similar T-cell engagers and PSMA-targeted therapies.
Market Dynamics
Industry Overview
The immuno-oncology field is rapidly evolving, with significant interest in T-cell engaging therapies. Competition is high with various companies working on related approaches.
Positioning
LAVA Therapeutics focuses on gamma-delta T cells, offering a potentially differentiated approach compared to alpha-beta T cell engagers. However, its clinical programs are in early stages.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is substantial, projected to reach billions of dollars. LAVA Therapeutics' potential market share depends on the clinical success and commercialization of its product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary Gammabody platform
- Focus on gamma-delta T cells, a potentially differentiated approach
- Early-stage clinical programs showing promise
Weaknesses
- Early-stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on the success of its lead product candidates
Opportunities
- Positive clinical trial results could lead to partnerships and funding
- Expansion of Gammabody platform to new targets and indications
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other immuno-oncology companies
- Regulatory hurdles
- Market adoption challenges
Competitors and Market Share
Key Competitors
- XOMA (XOMA)
Competitive Landscape
LAVA Therapeutics competes with other immuno-oncology companies developing T-cell engaging therapies and other cancer treatments. It's competitive advantage relies on its Gammabody platform and focus on gamma-delta T cells.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is tied to the advancement of its clinical programs.
Future Projections: Future growth depends on clinical trial results, regulatory approvals, and potential partnerships.
Recent Initiatives: Advancement of LAVA-051 and LAVA-1207 clinical trials.
Summary
LAVA Therapeutics is a developing biotech company with a unique focus on gamma-delta T cell engagers for cancer treatment. Its strength lies in its innovative Gammabody platform, but its early clinical stage and limited resources present challenges. Positive clinical trial results are crucial for the company's growth and success. Market competition and regulatory hurdles also pose significant threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated. Financial data is illustrative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LAVA Therapeutics NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-25 | CEO, President & Executive Director Mr. Stephen Allen Hurly M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.lavatherapeutics.com |
Full time employees 34 | Website https://www.lavatherapeutics.com | ||
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.